Zydus Wellness Ltd Share Price

Daily Index View : SENSEX as on 25/08/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 -5% 🔍 Key Level to Watch: 77512 🔄 Current Market Surface: The trend will stay Positive until the market stay above 77512 That’s 143 points away from the last day Closing Price of 77369 ATR 565 2. Demand & Supply PROBABILITY Force is Demand & Supply is High -15% Last 3 days market has been flatish on downside compared to ATR, so supply has very strong firepower — it just needs sentiment support 24 Aug 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) +1,181.66 +2,493.41 3. Reflexivity PROBABILITY First Half is Mildly Supportive to Bearish Momentum for at least first half -5% Last day market fell Intraday around 25–50% of the 8-day average ATR, so downside momentum should remain intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by 155 16% Dow jones future (live) 53,550 Up/Donw by +61.0 Hang seng (Live) 25517 Up/Donw by -5 Nikki 225 (Live) 65856 Up/Donw by 328 Sentiments: Dow Jones Futures is Trading Flat to Positive & HANG SENG Index is trading Flat to Negative Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias Top stock to watchout

Zydus Wellness Share Price: Analyst sees 23% upside on FMCG growth; sets Rs 750 target

Zydus Wellness Share Price: Analyst sees 23% upside on FMCG growth; sets Rs 750 target

Zydus Wellness Q1FY26 Net Sales up 74.46% YoY to Rs 153 crore

Pharma Stocks Surge After Strong Q1 Earnings Boost Sector Sentiment

The pharmaceutical sector remained in focus after several drug manufacturers reported strong Q1 FY27 earnings, supported by healthy domestic demand, robust export sales, and improved operating margins. Stocks such as Navin Fluorine and Neuland Laboratories rallied sharply after posting better-than-expected quarterly results, lifting overall sentiment in the pharma space. Analysts believe that improving product mix, higher exports, and stable raw material costs have contributed to stronger profitability. nvestors are also closely tracking the outlook for the US generics market, regulatory approvals, and new product launches, which are expected to drive future growth. Companies with diversified product portfolios, strong R&D capabilities, and consistent earnings continue to attract long-term investor interest despite global economic uncertainty. The healthcare sector is generally considered defensive during periods of market volatility, making fundamentally strong pharma companies an important part of diversified investment portfolios. Market participants will continue to monitor upcoming earnings, USFDA inspections, and export trends for further direction Learning Outcome: When analysing pharmaceutical companies, investors should focus on revenue growth, operating margins, R&D investments, regulatory approvals, export performance, and product pipeline rather than only quarterly profits. Companies with strong innovation and consistent compliance often create long-term shareholder value

Pharma Stocks Under Pressure as U.S. Tariff Proposal Raises Export Concerns

The Nifty Pharma index declined around 1.6% after U.S. President Donald Trump announced a phased tariff plan on imported generic medicines, with a proposed two-year transition period before implementation. Although the tariffs are not expected to take effect immediately, the announcement weighed on investor sentiment across Indian pharmaceutical stocks. The U.S. remains the largest export market for Indian generic drug manufacturers, making any policy changes closely watched by investors. If implemented, higher tariffs could increase costs for Indian exporters and impact their price competitiveness in one of their most important overseas markets. This has led to concerns about future revenue growth for companies with significant exposure to the U.S. However, the proposed transition period gives pharmaceutical companies time to evaluate their supply chains, pricing strategies, and manufacturing footprint. Investors will now closely monitor further policy announcements from the U.S., along with management commentary from Indian pharma companies regarding the potential financial impact and their plans to mitigate these challenges. While the news has affected short-term sentiment, the long-term outlook for the sector will continue to depend on product launches, regulatory approvals, research capabilities, and geographical diversification rather than a single policy announcement. Learning Outcome: Global policy decisions can significantly influence export-oriented industries. Investors should evaluate how dependent a company is on specific international markets and assess its ability to adapt to regulatory changes before making long-term investment decisions.